MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Apricus Biosciences Company Profile (NASDAQ:APRI)

Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $2.32 (392.91% upside)

Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)
Show:
DateFirmActionRatingPrice TargetActions
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Dawson JamesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Roth CapitalDowngradeBuy -> Neutral$1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015Ascendiant Capital MarketsInitiated CoverageBuy$2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2014Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Apricus Biosciences (NASDAQ:APRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/9/2016Q116($0.09)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2($0.13)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.10)($0.13)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q4($0.12)($0.09)$1.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.10)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.04)$0.05$5.45 million$5.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.09)($0.08)($0.09)
Q2 20162($0.10)($0.06)($0.08)
Q3 20162($0.08)($0.07)($0.08)
Q4 20162($0.05)($0.03)($0.04)
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)
Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Apricus Biosciences (NASDAQ:APRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
DateHeadline
06/24/16 08:36 AMAre Analysts Bearish Apricus Biosciences Inc (NASDAQ:APRI) After Last Week? - Press Telegraph
06/24/16 08:36 AMStocks Analysts Ranking Summary: Apricus Biosciences, Inc (NASDAQ:APRI) , GlaxoSmithKline PLC (NYSE:GSK) - Street Updates
06/24/16 08:36 AMHC Stocks Growth: Pfizer Inc. (NYSE:PFE), Apricus Biosciences Inc (NASDAQ:APRI) - share market updates (press release)
06/21/16 02:29 PMApricus Biosciences, Inc (APRI) Current Analyst Ratings - Fiscal Standard
06/21/16 11:46 AMETF’s with exposure to Apricus Biosciences, Inc. : June 21, 2016 -
06/19/16 07:17 AMApricus Biosciences, Inc (APRI) Analyst Price Targets For The Coming Week - Fiscal Standard
06/14/16 07:35 AMApricus Biosciences, Inc (NASDAQ:APRI) Yearly Sales Estimate At $11.92 - Investor Newswire
06/08/16 11:00 AMNow Available: Raynauds Disease Global Clinical Trials Review, H1, 2016
06/07/16 02:35 PMBiocom Appoints New Directors to its Board
06/01/16 02:36 PMApricus Biosciences, Inc (NASDAQ:APRI) Quarterly EPS Estimate At $-0.070 - Investor Newswire - Apricus Biosciences, Inc (NASDAQ:APRI) Quarterly EPS Estimate At $-0.070Investor NewswireFirst Call stated that Apricus Biosciences, Inc (NASDAQ:APRI) can touch $1.790 in coming one year. For the next quarter, the per-share earnings target is $-0.070 and for ongoing fiscal at $-0.180. EPS target for next year is $-0.010 versus the mean EPS ...and more »
06/01/16 10:57 AMStock Review and Earnings Check on Apricus Biosciences, Inc (NASDAQ:APRI) - HNN - Stock Review and Earnings Check on Apricus Biosciences, Inc (NASDAQ:APRI)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Apricus Biosciences, Inc ...and more »
05/30/16 08:43 AMStock Rating Review for Apricus Biosciences, Inc (NASDAQ:APRI) - HNN - Stock Rating Review for Apricus Biosciences, Inc (NASDAQ:APRI)HNNCovering equity analysts presently have a consensus stock rating of 2.5 on shares of Apricus Biosciences, Inc (NASDAQ:APRI). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating ...and more »
05/30/16 08:43 AMPerformance at a Glance on Apricus Biosciences, Inc. (NASDAQ:APRI) - HNN - Performance at a Glance on Apricus Biosciences, Inc. (NASDAQ:APRI)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Apricus Biosciences, Inc. (NASDAQ:APRI)'s stock has performed at various points in its past. Currently ...
05/28/16 05:21 PMApricus Biosciences, Inc (NASDAQ:APRI) Impact Score At 97 - RealistInvestor.com - Apricus Biosciences, Inc (NASDAQ:APRI) Impact Score At 97RealistInvestor.comAlpha One explored various online articles released on Apricus Biosciences, Inc (NASDAQ:APRI), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content ...and more »
05/27/16 08:35 AMApricus Biosciences Incorporated (NASDAQ:APRI) Sellers Increased By 6.2% Their Shorts - Wall Street Hints and News - Apricus Biosciences Incorporated (NASDAQ:APRI) Sellers Increased By 6.2% Their ShortsWall Street Hints and NewsApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The company has a market cap of $24.86 million. The Firm primarily focuses on the development and commercialization of products and product candidates in ...
05/26/16 05:31 PMAre Analysts Bullish Apricus Biosciences Inc (NASDAQ:APRI) After Last Week? - Wall Street Hints and News - Are Analysts Bullish Apricus Biosciences Inc (NASDAQ:APRI) After Last Week?Wall Street Hints and NewsOut of 4 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Apricus Bioscience Inc has been the topic of 6 analyst reports since August 6, 2015 according to ...
05/25/16 08:41 AMEarnings Review and Stock Rundown for Apricus Biosciences, Inc (NASDAQ:APRI) - Wall Street Hints and News - Earnings Review and Stock Rundown for Apricus Biosciences, Inc (NASDAQ:APRI)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Apricus Biosciences, Inc (NASDAQ:APRI) to ...and more »
05/23/16 10:22 AMStock Rating Review for Apricus Biosciences, Inc (NASDAQ:APRI) - Wall Street Hints and News - Stock Rating Review for Apricus Biosciences, Inc (NASDAQ:APRI)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 2 on shares of Apricus Biosciences, Inc (NASDAQ:APRI). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating ...and more »
05/20/16 10:31 PMAPRICUS BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) - Item 5.07. Submission of Matters to a Vote of Security Holders. On May 20, 2016, Apricus Biosciences, Inc. (the "Company") held its 2016 Annual Meeting of Stockholders (the "Annual Meeting"). The following is a brief description of each matter submitted to ...
05/20/16 03:29 PMAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 09:17 PMETF’s with exposure to Apricus Biosciences, Inc. : May 19, 2016 -
05/18/16 05:25 PMShare Recap and Earnings Focus on Apricus Biosciences, Inc (NASDAQ:APRI) - Wall Street Hints and News - Share Recap and Earnings Focus on Apricus Biosciences, Inc (NASDAQ:APRI)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Apricus Biosciences, Inc ...and more »
05/18/16 05:25 PMBroker Roundup For Apricus Biosciences, Inc (APRI) - Share Trading News - Broker Roundup For Apricus Biosciences, Inc (APRI)Share Trading News11/06/2015 – Apricus Biosciences, Inc was downgraded to “neutral” by analysts at Roth Capital. They now have a USD 1.5 price target on the stock. 08/13/2015 – Ascendiant Capital Markets began new coverage on Apricus Biosciences, Inc giving the ...and more »
05/18/16 09:35 AMRevenue Update on Apricus Biosciences Inc(NASDAQ:APRI) - Trade Calls - Revenue Update on Apricus Biosciences Inc(NASDAQ:APRI)Trade CallsApricus Biosciences Inc(NASDAQ:APRI) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 9, 2016. Company reported revenue of $626.00K. Analysts estimated a revenue of $920.00K. Earnings per ...Broker Roundup For Apricus Biosciences, Inc (APRI)Share Trading Newsall 2 news articles »
05/17/16 05:18 PMApricus Biosciences Inc 2015 Q4 Institutional Investor Sentiment Better Than Expected - Wall Street Hints and News - Apricus Biosciences Inc 2015 Q4 Institutional Investor Sentiment Better Than ExpectedWall Street Hints and NewsApricus Biosciences Inc (NASDAQ:APRI) institutional sentiment increased to 2 in Q4 2015. Its up 0.87, from 1.13 in 2015Q3. The ratio has improved, as 12 hedge funds increased or opened new holdings, while 6 sold and decreased positions in Apricus ...Apricus Biosciences, Inc (NASDAQ:APRI) Annual Sales Estimate At $11.99Equities Focusall 2 news articles »
05/17/16 12:04 PMAPRICUS BIOSCIENCES, INC. Financials -
05/17/16 11:14 AMApricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/13/16 10:51 PMAPRICUS BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 10, 2016, Apricus Biosciences, Inc. (the "Company") received a Nasdaq Staff Deficiency letter indicating that, for the last thirty ...
05/13/16 03:25 PMAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S -
05/12/16 10:55 PMApricus Biosciences, Inc (APRI) Updated Broker Price Targets - Share Trading News - Apricus Biosciences, Inc (APRI) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Apricus Biosciences, Inc (APRI). The latest reports which are currently in issue on Thursday 12th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...HC Stocks Opinion: Herbalife Ltd. (HLF), BioDelivery Sciences International Inc. (BDSI), Apricus Biosciences Inc (APRI)share market updates (press release)all 2 news articles »
05/09/16 10:44 PMCheck on Analyst Ratings Apricus Biosciences, Inc (NASDAQ:APRI) - B.O.D.Y Confidential - Check on Analyst Ratings Apricus Biosciences, Inc (NASDAQ:APRI)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 2 on shares of Apricus Biosciences, Inc (NASDAQ:APRI). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale.and more »
05/09/16 05:36 PMEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q1 Earnings Report - Below are the earnings highlights for Apricus Biosciences, Inc. (APRI): -Earnings: -$2.51 million in Q1 vs. -$6.41 million in the same period last year. -EPS: -$0.09 in Q1 vs. -$0.13 in the same period last year. -Analysts projected -$0.09 per share ...
05/09/16 06:49 AMApricus reports 1Q loss -
05/09/16 06:26 AMApricus Biosciences Provides Corporate Update and First Quarter Financial Results - [at noodls] - SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results ...
05/09/16 06:07 AMQ1 2016 Apricus Biosciences Inc Earnings Release - Before Market Open -
05/09/16 06:04 AMAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/08/16 05:52 PMAfter Last Week What Do Analysts Think Of Apricus Biosciences, Inc (APRI) - Share Trading News - NYSE Journal (press release)After Last Week What Do Analysts Think Of Apricus Biosciences, Inc (APRI)Share Trading News10/28/2014 – Apricus Biosciences, Inc had its “hold” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 1.5 price target on the stock. The share price of Apricus Biosciences, Inc (APRI) was down -2.36% during the last trading ...Earning Reports Updates: Apricus Biosciences Inc (NASDAQ:APRI)NYSE Journal (press release)Apricus Biosciences, Inc (NASDAQ:APRI) Comprehensive Income At $0 Millions For Quarter Closed 2014-03-31Enterprise Leaderall 3 news articles »
05/06/16 05:42 PMHow Analysts Feel About Apricus Biosciences Inc (NASDAQ:APRI)? - B.O.D.Y Confidential - How Analysts Feel About Apricus Biosciences Inc (NASDAQ:APRI)?B.O.D.Y ConfidentialOut of 4 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Apricus Bioscience Inc has been the topic of 6 analyst reports since August 6, 2015 according to ...and more »
05/04/16 10:49 PMPacira Pharmaceuticals (NASDAQ:PCRX) Issued With 'Buy' Rating From Mizuho Securities - Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Anacor Pharmaceuticals. Barclays Capital initiated the stock on January 21 with "Equal-Weight" rating. Mizuho Securities on Tuesday ...
05/04/16 10:49 PMWhat Wall Street is saying about Pacira Pharmaceuticals (PCRX) - Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Anacor Pharmaceuticals. Pacira Pharmaceuticals Inc with TICKER NASDAQ:PCRX had its stock rating noted as "Reiterated" with the ...
05/04/16 10:49 PMThe corrected release follows: - In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, "2H 2016" should instead be "Q3 2016." SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE ...
05/03/16 05:45 PMApricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction ... - ForexTV.com - Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction ...ForexTV.comSAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) — Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros® and erectile dysfunction ...
05/03/16 05:45 PMApricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results - GlobeNewswire (press release) - Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial ResultsGlobeNewswire (press release)SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2016 financial ...
05/03/16 05:45 PMCORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing ... - Nasdaq - CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing ...NasdaqSAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros® and erectile dysfunction ("ED") ...and more »
05/03/16 01:40 PMCORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population - [at noodls] - ?In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, '2H 2016' should instead be 'Q3 ...
05/03/16 06:20 AMApricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population - [at noodls] - Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine Vitaros U.S. NDA Re-Submission Remains on Schedule for 2H 2016 SAN DIEGO, May 03, 2016 ...
05/03/16 06:20 AMApricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results - [at noodls] - SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's ...
05/02/16 06:02 PMAverage Analyst Rating for Apricus Biosciences, Inc (NASDAQ:APRI) - B.O.D.Y Confidential - Average Analyst Rating for Apricus Biosciences, Inc (NASDAQ:APRI)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 2 on Apricus Biosciences, Inc (NASDAQ:APRI) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
04/28/16 06:02 PMAre Analysts Bullish Apricus Biosciences Inc (NASDAQ:APRI) After Last Week? - B.O.D.Y Confidential - Are Analysts Bullish Apricus Biosciences Inc (NASDAQ:APRI) After Last Week?B.O.D.Y ConfidentialOut of 4 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Apricus Bioscience Inc has been the topic of 6 analyst reports since August 6, 2015 according to ...
04/28/16 03:35 PMAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events -
About Apricus Biosciences

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company focused on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has one approved drug, Vitaros, which uses the NexACT delivery system, and is approved for the treatment of erectile dysfunction (ED) in Canada and through the European Decentralized Procedure (DCP) in Europe. The Company's other pipeline includes RayVa, Fispemifene and Femprox. RayVa utilizes the Company's permeation enhancer for the treatment of Raynaud's phenomenon secondary to scleroderma. Fispemifene a tissue-specific selective estrogen receptor modulator (SERM) used for the treatment of secondary hypogonadism. Femprox is used for the treatment of female sexual interest and arousal disorder (FSIAD). The Company owns or exclusively licenses approximately 331 issued patents and 194 patent applications.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APRI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.47
  • 50 Day Moving Average: $0.425
  • 200 Day Moving Average: $0.806
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $25.40M
  • Current Quarter EPS Consensus Estimate: $-0.180 EPS
Additional Links:
Apricus Biosciences (NASDAQ:APRI) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha